MEDIA

NEWS ARCHIVES

Interface Biologics Announces New VP Finance
Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the addition of Mr. Kevin Palmer to the IBI management team as Vice President of Finance.

Toronto, Canada, May 31, 2011 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the addition of Mr. Kevin Palmer to the IBI management team as Vice President of Finance.

Mr. Palmer joins IBI with over fifteen (15) years of Canadian and international management experience in finance and operations primarily with life sciences and medical device companies. Prior to joining IBI, Kevin worked as Director, Finance (Operations) & Controller at St. Jude Medical Canada, Inc., a subsidiary of this multi-billion dollar publicly traded medical device manufacturer (NYSE: SJT). Prior to SJT, he was Director, Finance & Controller at Affinum Pharmaceuticals, Inc., an early stage biotech company focused on the development and commercialization of novel anti-infective compounds. Kevin has also held senior Finance positions at Fresenius Medical Care Canada, Inc. (NASDAQ: FMS) and Boston Scientific Corporation (NYSE: BSC) at their headquarters in Massachusetts. Kevin started his career at Deloitte & Touche and is a Chartered Accountant and a B.Comm graduate of University of Toronto.

"We are very excited to have Kevin join the Interface Biologics leadership team" said Tom Reeves, President and CEO of Interface Biologics, Inc.. "He brings a rare combination of senior financial management experience in both early stage biotech and large multinational medical device companies which will be an invaluable asset for IBI as we transition to a fully fledged commercial stage company".

About Interface Biologics, Inc.
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without the need for heparin, anti-infective polymers, and programmable combination drug delivery devices. IBI, a University of Toronto spinoff, is now located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit www.interfacebiologics.com

FOR FURTHER INFORMATION PLEASE CONTACT:
Julie Fotheringham - Partner, Hageman Communications
416-951-7988
Julie.fotheringham@hageman.ca

Powered by Innovasium